Matthew Korenberg's Insider Trades & SAST Disclosures
Matthew Korenberg's most recent trade in Palvella Therapeutics Inc. was a trade of 123,559 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew Korenberg.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Palvella Therapeutics Inc. | Matthew Korenberg | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 123,559 | 123,559 | - | - | Non-Qualified Stock Option (right to buy) | |
| Palvella Therapeutics Inc. | Matthew Korenberg | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 5,373 | 5,373 | - | - | Incentive Stock Option (right to buy) | |
| Palvella Therapeutics Inc. | Matthew Korenberg | CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 167,100 | 167,100 | - | - | Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 9,377 | 42,436 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.84 per share. | 20 Sep 2024 | 9,377 | 60,549 (0%) | 0% | 52.8 | 495,481 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 101.60 per share. | 20 Sep 2024 | 7,090 | 50,978 (0%) | 0% | 101.6 | 720,379 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 104.10 per share. | 20 Sep 2024 | 6,275 | 50,777 (0%) | 0% | 104.1 | 653,238 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 49.99 per share. | 20 Sep 2024 | 4,982 | 57,052 (0%) | 0% | 50.0 | 249,050 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 4,982 | 395 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 100.05 per share. | 20 Sep 2024 | 2,481 | 58,068 (0%) | 0% | 100.1 | 248,228 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 395 | 0 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 49.99 per share. | 20 Sep 2024 | 395 | 51,172 (0%) | 0% | 50.0 | 19,746 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 102.05 per share. | 20 Sep 2024 | 201 | 50,777 (0%) | 0% | 102.1 | 20,513 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 3,340 | 18,500 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.94 per share. | 16 Sep 2024 | 3,340 | 54,008 (0%) | 0% | 60.9 | 203,540 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.00 per share. | 16 Sep 2024 | 1,938 | 52,070 (0%) | 0% | 105 | 203,490 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.75 per share. | 16 Sep 2024 | 914 | 50,424 (0%) | 0% | 55.8 | 50,956 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 914 | 25,949 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 849 | 12,452 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.49 per share. | 16 Sep 2024 | 849 | 50,788 (0%) | 0% | 58.5 | 49,658 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 671 | 5,377 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 49.99 per share. | 16 Sep 2024 | 671 | 50,987 (0%) | 0% | 50.0 | 33,543 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.00 per share. | 16 Sep 2024 | 485 | 49,939 (0%) | 0% | 105 | 50,925 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.00 per share. | 16 Sep 2024 | 472 | 50,316 (0%) | 0% | 105 | 49,560 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.00 per share. | 16 Sep 2024 | 319 | 50,668 (0%) | 0% | 105 | 33,495 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 105.02 per share. | 22 Aug 2024 | 6,177 | 54,722 (0%) | 0% | 105.0 | 648,684 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 106.32 per share. | 22 Aug 2024 | 5,212 | 49,510 (0%) | 0% | 106.3 | 554,147 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 105.13 per share. | 22 Aug 2024 | 4,275 | 60,899 (0%) | 0% | 105.1 | 449,439 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 104.09 per share. | 22 Aug 2024 | 2,037 | 65,174 (0%) | 0% | 104.1 | 212,040 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 105.54 per share. | 22 Aug 2024 | 1,157 | 67,211 (0%) | 0% | 105.5 | 122,110 | Common Stock |
| Lifecore Biomedical Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 24,554 | 24,554 (0%) | 0% | - | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Sale of securities on an exchange or to another person at price $ 98.50 per share. | 09 Aug 2024 | 18,245 | 68,368 (0%) | 0% | 98.5 | 1,797,133 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & Chief Operating | Other type of transaction at price $ 60.71 per share. | 28 Jun 2024 | 350 | 86,613 (0%) | 0% | 60.7 | 21,247 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & Chief Operating | Sale of securities on an exchange or to another person at price $ 85.08 per share. | 13 May 2024 | 13,638 | 86,783 (0%) | 0% | 85.1 | 1,160,356 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & Chief Operating | Sale of securities on an exchange or to another person at price $ 84.54 per share. | 13 May 2024 | 3,440 | 100,421 (0%) | 0% | 84.5 | 290,828 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & Chief Operating | Sale of securities on an exchange or to another person at price $ 85.68 per share. | 13 May 2024 | 520 | 86,263 (0%) | 0% | 85.7 | 44,556 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | PRESIDENT & CHIEF OPERATING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 58,544 | 58,544 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 14,416 | 103,861 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.65 per share. | 15 Feb 2024 | 4,778 | 89,445 (0%) | 0% | 74.7 | 356,678 | Common Stock |
| Ligand Pharmaceuticals, In... | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.31 per share. | 02 Jan 2024 | 2,917 | 94,223 (0%) | 0% | 72.3 | 210,928 | Common Stock |
| Ligand Pharmaceuticals, In... | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.61 per share. | 05 Dec 2023 | 1,984 | 97,140 (0%) | 0% | 59.6 | 118,266 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | PRESIDENT & CHIEF OPERATING | Other type of transaction at price $ 56.78 per share. | 30 Jun 2023 | 376 | 99,124 (0%) | 0% | 56.8 | 21,349 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 24,628 | 24,628 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,069 | 98,748 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.98 per share. | 15 Feb 2023 | 2,890 | 89,679 (0%) | 0% | 73.0 | 210,912 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.29 per share. | 28 Dec 2022 | 3,859 | 92,569 (0%) | 0% | 66.3 | 255,813 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 25,967 | 25,967 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 14,000 | 96,428 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.90 per share. | 30 Nov 2022 | 3,593 | 82,428 (0%) | 0% | 72.9 | 261,930 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 27,714 | 86,021 (0%) | 0% | 0 | Common Stock | |
| Qualigen Therapeutics Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Other type of transaction at price $ 75.84 per share. | 30 Jun 2022 | 164 | 52,532 (0%) | 0% | 75.8 | 12,437 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 8,062 | 52,368 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 30,189 | 30,189 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,532 | 44,306 (0%) | 0% | 123.7 | 189,478 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 969 | 45,838 (0%) | 0% | 123.7 | 119,846 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 906 | 46,807 (0%) | 0% | 123.7 | 112,054 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Other type of transaction at price $ 85.91 per share. | 30 Jun 2021 | 247 | 39,690 (0%) | 0% | 85.9 | 21,220 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 969 | 39,443 (0%) | 0% | 172.5 | 167,114 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 906 | 40,412 (0%) | 0% | 172.5 | 156,249 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 434 | 41,318 (0%) | 0% | 172.5 | 74,848 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 11,591 | 11,591 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 10,819 | 41,752 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 4,803 | 32,373 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 2,305 | 28,241 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.01 per share. | 25 Jan 2021 | 1,440 | 30,933 (0%) | 0% | 156.0 | 224,654 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.01 per share. | 25 Jan 2021 | 671 | 27,570 (0%) | 0% | 156.0 | 104,683 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew Korenberg | EVP,Finance & Strategy and CFO | Other type of transaction at price $ 89.03 per share. | 30 Jun 2020 | 238 | 25,936 (0%) | 0% | 89.0 | 21,189 | Common Stock |
| Qualigen Therapeutics Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges